David Requena
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 7
- Liver physiology and pathology 3
-
- Cancer Genomics and Diagnostics 4
- Co-authors
- Robert M. Samstein (1 shared paper)Benjamin D. Greenbaum (1 shared paper)Nadeem Riaz (1 shared paper)Vladimir Makarov (1 shared paper)Luc G. T. Morris (1 shared paper)Sviatoslav M. Kendall (1 shared paper)Diego Chowell (1 shared paper)David Solit (1 shared paper)
- Journals
- PLoS ONE (4 papers)Frontiers in Immunology (3 papers)BMC Genomics (2 papers)Nature Communications (1 paper)Science Advances (1 paper)
- Partner nations
- United StatesPeruSpain
In The Last Decade
David Requena
36 papers receiving 1.5k citations
David Requena's Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 671
- Hepatology 159
- Cancer Research 148
- Immunology 117
- Infectious Diseases 92
Countries citing papers authored by David Requena
This map shows the geographic impact of David Requena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Requena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Requena more than expected).
Fields of papers citing papers by David Requena
This network shows the impact of papers produced by David Requena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Requena. The network helps show where David Requena may publish in the future.
Co-authors
The 25 scholars most cited alongside David Requena, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy Hit paper breakdown → | 2017 | 900 |
| 2 | 2017 | 133 | |
| 3 | 2020 | 46 | |
| 4 | 2014 | 37 | |
| 5 | 2021 | 35 | |
| 6 | 2017 | 32 | |
| 7 | 2015 | 29 | |
| 8 | 2020 | 28 | |
| 9 | 2021 | 26 | |
| 10 | 2017 | 24 | |
| 11 | 2016 | 22 | |
| 12 | 2017 | 20 | |
| 13 | 2022 | 20 | |
| 14 | 2015 | 18 | |
| 15 | 2017 | 18 | |
| 16 | 2013 | 17 | |
| 17 | 2015 | 17 | |
| 18 | 2015 | 15 | |
| 19 | 2020 | 14 | |
| 20 | 2023 | 14 |
About David Requena
David Requena is a scholar working on Hepatology, Cancer Research, Molecular Biology, Infectious Diseases and Microbiology, having authored 36 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cancer Genomics and Diagnostics (4 papers), vaccines and immunoinformatics approaches (4 papers), Tuberculosis Research and Epidemiology (3 papers), Liver physiology and pathology (3 papers), Developmental Biology and Gene Regulation (3 papers), Cancer Cells and Metastasis (2 papers) and Microbial infections and disease research (2 papers). The work is most often cited by research in Oncology (671 citations), Hepatology (159 citations), Cancer Research (148 citations), Immunology (117 citations) and Infectious Diseases (92 citations). David Requena has collaborated with scholars based in United States, Peru and Spain. Frequent co-authors include Robert M. Samstein, Benjamin D. Greenbaum, Nadeem Riaz, Vladimir Makarov, Luc G. T. Morris, Sviatoslav M. Kendall, Diego Chowell, David Solit, Naiyer A. Rizvi and Michael F. Berger. Their work appears in journals such as PLoS ONE, Frontiers in Immunology, BMC Genomics, Nature Communications and Science Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.